

PHARMACY POLICY STATEMENT

Marketplace

DRUG NAME	Juxtapid (lomitapide)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Juxtapid, approved by the FDA in 2012, is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Juxtapid (lomitapide) will be considered for coverage when the following criteria are met:

Homozygous Familial Hypercholesterolemia (HoFH)

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consultation with a cardiologist or lipid specialist; AND
3. Member has a diagnosis of homozygous familial hypercholesterolemia (HoFH) confirmed by one of the following:
 - a) Genetic testing confirmation of two mutant alleles in the *LDLR*, *Apo-B*, *PCSK9*, or *LDLRAP1* gene locus; OR
 - b) LDL-C > 500 mg/dL before any treatment or LDL-C > 300 mg/dL if treated with a lipid-lowering drug AND one of the following:
 - i) Cutaneous or tendon xanthoma before 10 years of age; OR
 - ii) Evidence of heterozygous familial hypercholesterolemia (HeFH) (i.e., total cholesterol > 250 mg/dL) in both parents; AND
4. Chart notes must include documentation of baseline LDL-C level above goal within the past 90 days; AND
5. Member is unable to achieve LDL-C goal (see Note) after trials with **both** of the following:
 - a) 90-day trial of a high-intensity statin (i.e., rosuvastatin ≥ 20mg, atorvastatin ≥ 40mg) together with ezetimibe. If intolerance occurs, a second attempt must be initiated with a moderate or low-intensity statin + ezetimibe;
 - b) 90-day trial with a PCSK9 inhibitor (e.g., Repatha or Praluent; prior authorization required) unless there is evidence of no LDL receptor function (receptor-negative type HoFH); AND
6. Juxtapid will be used as an adjunct to other lipid-lowering treatments (e.g., statins, ezetimibe, LDL apheresis, etc.), unless contraindicated or intolerant; AND
7. Prescriber attests that the member will be on a low-fat diet during treatment; AND
8. Juxtapid is not being concomitantly initiated with Evkeeza.
9. **Dosage allowed/Quantity limit:** Up to 60 mg once daily. See package insert for titration. (Max 60 capsules per 30 days [for the 20 mg or 30 mg capsules]; 30 capsules per 30 days for the 5 mg or 10 mg capsules)

NOTE: The LDL-C goals are <100 mg/dL for adults 18 years or older, < 135 mg/dL for children, and < 70 mg/dL for adults with clinical ASCVD

If all the above requirements are met, the medication will be approved for 6 months.

For **reauthorization**:

1. Chart notes along with recent labs have been provided showing a meaningful reduction of cholesterol levels (LDL-C, total cholesterol, apolipoprotein B, etc.) from baseline OR all cholesterol levels are at goal.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Juxtapid (lomitapide) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
7/22/2020	New policy for Juxtapid created.
04/05/2021	Added Praluent to list of alternative products. Changed trials to include Praluent in addition to Repatha and increased trial length to 90 days. Added a trial requirement for concomitant request of Juxtapid and Evkeeza. Updated genetic testing requirement to ask for specific alleles (previously not specified). Updated atorvastatin high-intensity requirement to reflect pediatric vs. adult dosing.
02/22/2022	Policy for Juxtapid transferred to new template. Corrected the quantity limit from 30/30 to 60/30; highest capsule strength is 30mg.
05/25/2023	Added references. Changed “baseline cholesterol” to “baseline LDL-C above goal.” Added receptor-negative as exception to PCSK9 requirement. Simplified statement regarding Evkeeza (does not prohibit using them together, but they may not be started at the same time).

References:

1. Juxtapid [Package insert]. Cambridge, MA: Aegerion Pharmaceuticals, Inc; 2020.
2. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *Eur Heart J*. 2014;35(32):2146-2157.
3. Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. *Core Evid*. 2019;14:19-30. Published 2019 Jul 1.
4. Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Manag Care Pharm*. 2013;19(2):139-149. doi:10.18553/jmcp.2013.19.2.139
5. Gidding SS, Champagne MA, de Ferranti SD, et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association [published correction appears in *Circulation*. 2015 Dec 22;132(25):e397]. *Circulation*. 2015;132(22):2167-2192. doi:10.1161/CIR.0000000000000297
6. France M, Rees A, Datta D, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. *Atherosclerosis*. 2016;255:128-139. doi:10.1016/j.atherosclerosis.2016.10.017
7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in *Eur Heart J*. 2020 Nov 21;41(44):4255]. *Eur Heart J*. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455

Effective date: 10/01/2023

Revised date: 05/25/2023